The combination therapy of exenatide and metformin reported better results than metformin alone in modulating anthropometric indexes, insulin sensitivity, and menstrual cycle frequency among overweight and obese PCOS patients [22, 27]. This evidence concerns the gene INS and polycystic ovary syndrome.